Effects of Kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 2, 1998, Pages 812-824

  Mello, Nancy K ^a   Negus, S Stevens ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREMAZOCINE; COCAINE; CYCLAZOCINE; ENADOLINE; KAPPA OPIATE RECEPTOR AGONIST; N (TETRAHYDROFURFURYL)NORMETAZOCINE; N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZO[B]THIOPHENE 4 ACETAMIDE; SPIRADOLINE;

ANIMAL EXPERIMENT; ARTICLE; COCAINE DEPENDENCE; DRUG EFFECT; DRUG POTENCY; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; BODY WEIGHT; COCAINE; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD; MACACA MULATTA; NARCOTICS; RECEPTORS, OPIOID, KAPPA; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; SELF ADMINISTRATION;

EID: 0032437428     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Archer S, Glick SD and Bidlack J (1996) Cyclazocine revisited. Neurochem Res 21:1369-1373.
2. Bergman J, Hassoun J and Schuster CR (1985) Behavioral effects of selected opiates and phencyclidine in the nondependent and cyclazocine-dependent rhesus monkey. J Pharmacol Exp Ther 235:463-469.
3. Bergman J and Spealman RD (1997) Opioid-cocaine interactions and schedule-controlled behavior of squirrel monkeys (submitted).
4. Brandt MR and France CP (1996) Discriminative stimulus effects of enadoline in pigeons. J Pharmacol Exp Ther 277:960-967.
5. Broadbear JH, Negus SS, Butelman ER, de Costa BR and Woods JH (1994) Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on κ-opioid agonists in the mouse writhing assay. Psychopharmacology 115:311-319.
6. 2 analysis of the respiratory depressant effects of alfentanil etonitazene ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys. J Pharmacol Exp Ther 264:145-151.
7. Butelman ER, France CP and Woods JH (1995) Agonist and antagonist effects of dynorphin A-d-13) in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 275:374-380.
8. Butelman ER, Negus SS, Ai Y, de Costa BR and Woods JH (1993a) Kappa opioid antagonist effects of systemically administered nor-binaltorphimine (nor-BNI) in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 257: 1269-1276.
9. Chavkin C, James IF and Goldstein A (1982) Dynorphin is a specific endogenous ligand of the κ opioid receptor. Science 215:413-415.
10. Clark JA, Liu L, Price M, Hersh B, Edelson M and Pasternak GW (1989) Kappa opiate receptor multiplicity: Evidence for two U50,488-sensitive kappa subtypes and a novel kappa subtype. J Pharmacol Exp Ther 251:461-468.
11. Crawford CA, McDougall SA, Bolanos CA, Hall S and Berger SP (1993) The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immuoreactivity. Psychopharmacology 120:392-399.
12. Daunais JB and McGinty JF (1994) Acute and chronic cocaine administration differentially alters striatal opioid and nuclear transcription factor mRNAs. Synapse 18:35-45.
13. Daunais JB and McGinty JF (1995) Cocaine binges differentially alter striatal preprodynorphin and zif/268 mRNAs. Mol Brain Res 29:201-210.
14. Daunais JB, Roberts DC and McGinty JF (1995) Short-term cocaine self-administration alters striatal gene expression. Brain Res Bull 37:523-527.
15. Davis RE, Calahan MJ, Dickerson M and Downs DA (1992) Pharmacological activity of CI-977, a selective kappa opioid agonist, in rhesus monkeys. J Pharmacol Exp Ther 261:1044-1049.
16. Devine DP, Leone P, Pocock D and Wise RA (1993) Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: In vivo microdialysis studies. J Pharmacol Exp Ther 266:1236-1246.
17. DiChiara G (1995) The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 38:95-137.
18. DiChiara G and Imperato A (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067-1080.
19. Donzanti BA, Althaus JS, Payson MM and VonVoigtlander PF (1992) Kappa agonist-induced reduction in dopamine release: Site of action and tolerance. Res Commun Chem Pathol Pharmacol 78:193-210.
20. Dykstra LA, Gmerek DE, Winger G and Woods JH (1987) Kappa opioids in rhesus monkeys. 1. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 242:413-420.
21. Emmerson PJ, Liu M-R, Woods JH and Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Ex Ther 271:1630-1637.
22. France CP, Medzihradsky F and Woods JH (1994) Comparison of kappa opioids in rhesus monkeys: Behavioral effects and receptor binding affinities. J Pharmacol Exp Ther 268:47-58.
23. Gatch MB, Negus SS, Mello NK, Archer S and Bidlack JM (1996) Effects of the structurally novel opioid 14a,14′b-[dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis(7,8- dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys. J Pharmacol Exp Ther 278:1282-1289.
24. Glick SD, Maisonneuve IM, Raucci J and Archer S (1995) Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681:147-152.
25. Gmerek DE, Dykstra LA and Woods JH (1987) Kappa opioids in rhesus monkeys. III. Dependence associated with chronic administration. J Pharmacol Exp Ther 242: 428-436.
26. Hanson GR, Singh N, Merchant K, Johnson M and Gibb W (1995) The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse. Drug Alcohol Depend 37:107-110.
27. Heidbreder CA, Babovic-Vuksanovic D, Shoaib M and Shippenberg T (1995) Development of behavioral sensitization to cocaine: Influence of kappa opioid receptor agonists. J Pharmacol Exp Ther 275:150-163.
28. Hokfelt T, Vincent SR, Dalsgaard CJ, Herrera-Marschitz M, Understedt U, Schultzberg M, Christensson I and Terenius L (1984) Some aspects on distribution and role of opioid peptides in the central and peripheral nervous system. In Central and Peripheral Endorphins: Basic and Clinical Aspects, ed. by E. E. Muller and A. R. Genazzani, pp. 1-16, Raven Press, New York.
29. Hurd YL and Herkenham M (1993) Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13:357-369.
30. Hyman SE and Nestler EJ (1996) Initiation and adaptation: A paradigm for understanding psychotropic drug action. Am J Psychiatry 153:151-162.
31. Jaffe JH and Brill L (1966) Cyclazocine, a long acting narcotic antagonist: Its voluntary acceptance as a treatment modality by narcotic abusers. Int J Addict 1:99-123.
32. Kuzmin AV, Semenova S, Gerrits MAFM, Zvartau EE and Van RJM (1997) Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice. Eur J Pharmacol 321:265-271.
33. Line SW, Markowitz H, Morgan KN and Strong S (1989) Evaluation of attempts to enrich the environment of single-caged non-human primates. In Animal Care and Use in Behavioral Research: Regulations, Issues, and Applications, ed. by J. W. Driscoll, pp. 103-117, National Agricultural Library, Beltsville, MD.
34. Loeb WF and Quimby FW (1989) The Clinical Chemistry of Laboratory Animals. New York, Pergamon Press.
35. Magnan J, Paterson SJ, Tavani A and Kosterlitz HW (1982) The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedeberg's Arch Pharmacol 319:197-205.
36. Maisonneuve IM, Archer S and Glick SD (1994) U50,488 a κ opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181:57-60.
37. Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H and Watson SJ (1994) Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study. J Comp Neurol 350:412-438.
38. Mansour A, Khachaturian H, Lewis ME, Akil H and Watson SJ (1987) Autoradiographic differentiation of mu, delta and kappa opioid receptors in rat forebrain and midbrain. J Neurosci 7:2445-2464.
39. Mansour A, Khachaturian H, Lewis ME, Akil H and Watson SJ (1988) Anatomy of CNS opioid receptors. Trends Neurosci 11:308-314.
40. Martin WR, Fraser HF, Gorodetzky CW and Rosenberg DE (1965) Studies of the dependence-producing potential of the narcotic antagonists 2-cyclopropylmethyl 2′-hydroxy-5,9-dimethyl-6,7-benzomorphan (cyclazocine, Win 20,740, ARC 11-C-3). J Pharmacol Exp Ther 150:426-436.
41. Martin WR, Gorodetzky CW and McClane TK (1966) An experimental study in the treatment of narcotic addicts with cyclazocine. Clin Pharmacol Ther 455-464.
42. McClure HM (1975) Hematologic, blood chemistry and cerebrospinal fluid data for the rhesus monkey. In The Rhesus Monkey, Vol. 2, ed. by G. H. Bourne, pp. 409-429, Academic Press, New York.
43. Mello NK, Mendelson JH, Bree MP and Lukas S (1990) Buprenorphine and naltrexone effects on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 254:926-939.
44. Mello NK and Negus SS (1996) Preclinical evaluation of pharmacotherapies for treatment of cocaine and opiate abuse using drug self-administration procedures. Neuropsychopharmacology 14:375-424.
45. Mendelson JH and Mello NK (1996) Management of cocaine abuse and dependence. N Engl J Med 334:965-972.
46. Morrison DF (ed) (1990) Multivariate Statistical Methods. McGraw-Hill, New York.
47. Negus SS, Burke TF, Medzihradsky F and Woods JH (1993) Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: Antagonism by quadazocine. J Pharmacol Exp Ther 267:896-903.
48. Negus SS, Butelman ER, Chang KJ, DeCosta BR, Winger G and Wood JH (1994) Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys. J Pharmacol Exp Ther 270:1025-1034.
49. Negus SS, Lamas X and Mello NK (1996) Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 278:879-890.
50. Negus SS, Mello NK, Portoghese P and Lin C-E (1997) Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282:44-55.
51. Negus SS, Mello NK, Portoghese PS, Lukas SE and Mendelson JH (1995) Role of delta opioid receptors in the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 273:1245-1256.
52. Nida Epidemiologic Trends in Drug Abuse. Volume I (1997) Highlights and Executive Summary. National Institute on Drug Abuse, NIH Publ. No. 98-4207, pp. 82.
53. Nock B, Giordano AL, Cicero TJ and O'Conor LH (1990) Affinity of drugs and peptides for U69,593-sensitive and -insensitive kappa opiate binding sites: The U69,593-insensitive site appears to be the β-endorphin specific epsilon receptor. J Pharmacol Exp Ther 254:412-419.
54. Pfeiffer A, Branti V, Herz A and Emrich HM (1986) Psychotomimesis mediated by k opiate receptors. Science 233:774-776.
55. Portoghese PS, Lipkowski AW and Takemori AE (1987) Binaltorphimine and norbinaltorphimine, potent and selective kappa opioid receptor antagonists. Life Sci 40:1287-1292.
56. Reece PA, Sedman AJ, Rose S, Wright DS, Dawkins R and Rajagopalan R (1994) Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J Clin Pharmacol 34:1126-1132.
57. Rimoy GH, Bhaskar NK, Wright DM and Rubin PC (1991) Mechanism of diuretic action of spiradoline (U-62066E): A kappa opioid receptor agonist in the human. J Clin Pharmacol 32:611-615.
58. Rothman RB, Bykov V, DeCosta BR, Jacobson AE, Rice KC and Brady LS (1990) Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides 11:311-331.
59. Shippenberg TS, LeFevour A and Heidbreder CH (1996) Kappa-opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 276:545-554.
60. Smith MA and Picker MJ (1995) Examination of the kappa agonist and antagonist properties of opioids in the rat drug discrimination procedure: Influence of training dose and intrinsic efficacy. Behav Pharmacol 6:703-717.
61. Spanagel R, Herz A and Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89:2046-2050.
62. Spealman RD and Bergman J (1992) Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids. J Pharmacol Exp Ther 261:607-615.
63. Spealman RD and Bergman J (1994) Opioid modulation of the discriminative stimulus effects of cocaine: Comparison of μ, κ and δ agonists in squirrel monkeys discriminating low doses of cocaine. Behav Pharmacol 5:21-31.
64. Steiner H and Gerfen CR (1995) Dynorphin opioid inhibition of cocaine-induced, D1 dopamine receptor-mediated immediate-early gene expression in the striatum. J Comparative Neurol 353:200-212.
65. Su TP (1985) Further demonstration of kappa opioid binding sites in the brain: Evidence for heterogeneity. J Pharmacol Exp Ther 232:144-148.
66. Suzuki T, Shiozaki Y, Masukawa Y, Misawa M and Nagase H (1992) The role of mu-and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn J Pharmacol 58:435-442.
67. Takemori AE, Ho BY, Naeseth JS and Portoghese PS (1988) Norbinaltorphimine (norBNI), a highly selective kappa-opioid receptor antagonist in analgesia and receptor binding assays. J Pharmacol Exp Ther 246:255-258.
68. Ukai M, Mizutani M and Kameyama T (1994) Opioid peptides selective for receptor types modulate cocaine-induced behavioral responses in mice. Yakubutsu Seishin Kodo 14:153-159.
69. Unterwald EM, Rubenfeld JM and Kreek MJ (1994) Repeated cocaine administration upregulates κ and μ, but not 6, opioid receptors. NeuroReport 5:1613-1616.
70. Wood PL (1982) Multiple opiate receptors: Support for unique mu, delta and kappa sites. Neuropsychopharmacology 21:487-497.
71. 2 opioid receptors. Proc Natl Acad Sci USA 85:4061-4065.